Se connecter

Bibliographies thématiques / Myers, Kevin

Sommaire

Articles de revues
Livres
Chapitres de livres

Littérature scientifique sur le sujet « Myers, Kevin »

Auteur : Grafiati

Publié le 25 juillet 2024

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Myers, Kevin ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Myers, Kevin"

1

Myers, Edward A., Luigie Alequín, Ayanna Browne, et al. "Population divergence in co-distributed Caribbean landfrogs (Eleutherodactylidae: Eleutherodactylus) along the Soufrière volcanic slope of Guadeloupe Island, Lesser Antilles." Zoological Journal of the Linnean Society 202, no. 4 (2024): 1–13. https://doi.org/10.1093/zoolinnean/zlae128.

Texte intégral

Résumé :

Myers, Edward A, Alequín, Luigie, Browne, Ayanna, Mulder, Kevin P, Rivera, Danielle, Esposito, Lauren A, Bell, Rayna C, Hedges, S Blair (2024): Population divergence in co-distributed Caribbean landfrogs (Eleutherodactylidae: Eleutherodactylus) along the Soufrière volcanic slope of Guadeloupe Island, Lesser Antilles. Zoological Journal of the Linnean Society (zlae128) 202 (4): 1-13, DOI: 10.1093/zoolinnean/zlae128, URL: https://doi.org/10.1093/zoolinnean/zlae128

Styles APA, Harvard, Vancouver, ISO, etc.

2

Macpherson, Jim. "Struggles for a Past: Irish and Afro-Caribbean Histories in England, 1951–2000. By Kevin Myers." Twentieth Century British History 30, no. 4 (2018): 618–20. http://dx.doi.org/10.1093/tcbh/hwy030.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Gerrard, Jessica. "Struggles for a past: Irish and Afro-Caribbean histories in England, 1951–2000, by Kevin Myers." History of Education 46, no. 4 (2016): 533–34. http://dx.doi.org/10.1080/0046760x.2016.1181798.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Arriens, C., A. Askanase, R. Furie, et al. "AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1463.1–1463. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3881.

Texte intégral

Résumé :

BackgroundDeucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis[1,2]. Deucravacitinib demonstrated efficacy across the primary endpoint and all key secondary endpoints in a phase 2 trial in patients with systemic lupus erythematosus (SLE)[3].ObjectivesHere, we describe 2 phase 3 trials currently underway to assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the p

Styles APA, Harvard, Vancouver, ISO, etc.

5

Choy, E., S. Henning, M. Brazil, et al. "AB0347 TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1299.1–1299. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2356.

Texte intégral

Résumé :

BackgroundA previous real-world study has reported the characteristics, treatment patterns and clinical outcomes of patients with rheumatoid arthritis (RA) who received abatacept in UK clinical practice.1,2 However, many of the eligible population received abatacept monotherapy rather than as indicated. A subgroup analysis of patients treated with abatacept in combination with methotrexate (ABA + MTX) was therefore undertaken to explore the treatment effect in this specific patient population.ObjectivesPresent a subgroup analysis describing the clinical outcomes of patients with RA treated wit

Styles APA, Harvard, Vancouver, ISO, etc.

6

Curtis, J., K. Winthrop, B. Chan, et al. "FRI0314 ANNUAL DIAGNOSTIC PREVALENCE OF ANKYLOSING SPONDYLITIS (AS) IN THE UNITED STATES USING MEDICARE AND MARKETSCAN DATA." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 747.1–748. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4246.

Texte intégral

Résumé :

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that affects the axial skeleton and sacroiliac joints, and can be classified as ankylosing spondylitis (AS) or non-radiographic (nr)-axSpA.1A 2016 analysis estimated the US diagnostic prevalence of axSpA to be 0.2% and AS to be 0.1%.2Previous studies use disparate populations and diagnostic definitions;3,4it is therefore unclear how AS prevalence has changed over time.Objectives:To investigate the annual diagnostic prevalence of AS in US healthcare insurance claims databases.Methods:A retrospective, observational coho

Styles APA, Harvard, Vancouver, ISO, etc.

7

Korman, N. J., T. Passeron, K. B. Gordon, et al. "AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1774–75. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1533.

Texte intégral

Résumé :

BackgroundTyrosine kinase 2 (TYK2) is an intracellular enzyme involved in IL-23 signaling that is important in the pathogenesis of immune-mediated diseases, including psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE). Deucravacitinib is a first-in-class, oral, selective, allosteric TYK2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib uniquely binds to the TYK2 regulatory domain rather than the more conserved catalytic domain at which Janus kinase (JAK) 1/2/3 inhibitors bind. Deucravacitinib was efficacious compare

Styles APA, Harvard, Vancouver, ISO, etc.

8

Deodhar, A., K. Winthrop, R. Bohn, et al. "SAT0370 TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1132.1–1133. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4201.

Texte intégral

Résumé :

Background:Comorbidities and extra-articular manifestations (EAMs) substantially increase disease burden and mortality risk in patients (pts) with ankylosing spondylitis (AS).1,2Tumour necrosis factor inhibitors (TNFi) are highly efficacious and effective in AS treatment (tx), and are used after inadequate response to non-steroidal anti-inflammatory drugs.3,4However, the impact of TNFi on the incidence of comorbidities and EAMs in pts with AS is unknown.5Objectives:To determine the incidence of comorbidities and EAMs in TNFi vs non-TNFi treated pts with AS in the US.Methods:This was a retrospe

Styles APA, Harvard, Vancouver, ISO, etc.

9

Winthrop, K., P. Nash, K. Yamaoka, et al. "THU0218 INCIDENCE AND RISK FACTORS FOR HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING UPADACITINIB." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 335–36. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2744.

Texte intégral

Résumé :

Background:Upadacitinib (UPA) is an oral JAK inhibitor approved for the treatment of rheumatoid arthritis (RA). The background rate of herpes zoster (HZ) in patients (pts) with RA is around 0.98/100 person years (PY)1. Pts with RA receiving JAK inhibitors have been reported to have an increased risk of HZ.Objectives:To evaluate the incidence and risk factors for HZ in pts with RA receiving UPA relative to active comparators in the Phase 3 clinical trial program.Methods:The incidence rate of HZ was determined in pts receiving UPA (as monotherapy [mono] or combination therapy) in five randomized

Styles APA, Harvard, Vancouver, ISO, etc.

10

Aletaha, D., P. J. Mease, R. Lippe, et al. "POS1026 PREDICTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT WEEK 56 IN PATIENTS WITH PSORIATIC ARTHRITIS WHO RECEIVED UPADACITINIB 15 MG ONCE DAILY: POOLED ANALYSIS OF TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 824.2–825. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1291.

Texte intégral

Résumé :

BackgroundUpadacitinib (UPA) 15 mg once daily (QD) has demonstrated efficacy and safety in patients with psoriatic arthritis (PsA) for up to 56 weeks in the Phase 3 SELECT-PsA 1 and 2 trials.1,2ObjectivesThis post hoc analysis of these studies explored the association of baseline characteristics and short-term responses with achievement of minimal disease activity (MDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) low disease activity (LDA).MethodsData were pooled from patients with prior inadequate response or intolerance to ≥1 non-biologic (b) DMARDs (SELECT-PsA 1) or ≥1 bDMARD

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "Myers, Kevin"

1

Myers, Kevin. Kevin Myers: From the Irish Times Column 'an Irishmam's Diary'. Four Courts Press, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Watching the Door: A Memoir 1971-78. Lilliput Press, Limited, The, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Watching the Door: Drinking up, Getting down, and Cheating Death in 1970s Belfast. Counterpoint Press, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Watching the Door. Atlantic Books, 2008.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Myers, Kevin"

1

"English character and Kevin Myers identity." In Social Identities. Routledge, 2004. http://dx.doi.org/10.4324/9780203338674-9.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

"Policy, equality and inequality: from the past to the future Kevin Myers and Ian Grosvenor." In Schooling and Equality. Routledge, 2013. http://dx.doi.org/10.4324/9781315889405-20.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

"Adventure tourism as a series of memorable events: Women travellers’ walking experiences in New Zealand: Linda Myers and Kevin Hannam." In International Sports Events. Routledge, 2013. http://dx.doi.org/10.4324/9780203131237-21.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Taber, Douglass F. "Reactions of Alkenes: The Usami Synthesis of (−)-Pericosine E." In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0030.

Texte intégral

Résumé :

Dasheng Leow of the National Tsing Hua University used (Eur. J. Org. Chem. 2014, 7347) photolysis to activate the air oxidation of hydrazine to generate diimide, that then reduced 1 selectively to 2. Kevin M. Peese of Bristol-Myers Squibb effected (Org. Lett. 2014, 16, 4444) ring-closing metathesis of 3 followed by in situ reduction to form 4. Jitendra K. Bera of the Indian Institute of Technology Kanpur effected (J. Am. Chem. Soc. 2014, 136, 13987) gentle oxidative cleavage of cyclooctene 5 to the dialdehyde 6. Arumugam Sudalai of the National Chemical Laboratory observed (Org. Lett. 2014, 1

Styles APA, Harvard, Vancouver, ISO, etc.

5

Lambert, Tristan H. "Functional Group Interconversion." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0004.

Texte intégral

Résumé :

Chaozhong Li of the Shanghai Institute of Organic Chemistry reported (J. Am. Chem. Soc. 2012, 134, 10401) the silver nitrate catalyzed decarboxylative fluorination of carboxylic acids, which shows interesting chemoselectivity in substrates such as 1. A related decarboxylative chlorination was also reported by Li (J. Am. Chem. Soc. 2012, 134, 4258). Masahito Ochiai at the University of Tokushima has developed (Chem. Commun. 2012, 48, 982) an iodobenzene-catalyzed Hofmann rearrangement (e.g., 3 to 4) that proceeds via hypervalent iodine intermediates. The dehydrating agent T3P (propylphosphonic

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!